Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Exagen (XGN) Shares Issued (2020 - 2026)

Exagen filings provide 7 years of Shares Issued readings, the most recent being $295000.0 for Q1 2026.

  • On a quarterly basis, Shares Issued rose 48.99% to $295000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $19.2 million, a 16482.76% increase, with the full-year FY2025 number at $398000.0, up 1709.09% from a year prior.
  • Shares Issued hit $295000.0 in Q1 2026 for Exagen, up from -$3.0 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $18.6 million in Q2 2025 to a low of -$3.0 million in Q4 2025.
  • Median Shares Issued over the past 5 years was $139500.0 (2022), compared with a mean of $1.4 million.
  • Biggest five-year swings in Shares Issued: plummeted 181.17% in 2023 and later surged 4246.34% in 2025.
  • Exagen's Shares Issued stood at -$324000.0 in 2022, then soared by 177.78% to $252000.0 in 2023, then tumbled by 132.54% to -$82000.0 in 2024, then plummeted by 3604.88% to -$3.0 million in 2025, then soared by 109.71% to $295000.0 in 2026.
  • The last three reported values for Shares Issued were $295000.0 (Q1 2026), -$3.0 million (Q4 2025), and $3.4 million (Q3 2025) per Business Quant data.